DXCM - Company ID 0001093557
The table below shows DEXCOM INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.34B | $1.31B | $1.19B | $1.21B | $1.16B | $1.04B |
| Cost of revenue | $480.10M | $478.40M | $441.60M | $477.90M | $468.30M | $447.00M |
| Gross profit | $864.40M | $830.00M | $750.30M | $731.40M | $688.80M | $589.00M |
| R&D | $161.60M | $153.00M | $145.30M | $157.50M | $148.20M | $145.20M |
DEXCOM INC reported annual revenue of $4.66B for fiscal year 2025. That is up 15.6% from $4.03B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $573.30M (FY 2016) to $4.66B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $375.60M | $358.70M | $349.70M | $331.40M | $328.00M | $310.10M |
| Operating income | $327.20M | $318.30M | $255.30M | $242.50M | $212.60M | $133.70M |
| Income tax | $59.60M | $68.40M | $70.00M | $68.50M | $61.30M | $48.90M |
| Net income | $275.10M | $249.10M | $199.50M | $283.80M | $179.80M | $105.40M |
| EPS (diluted) | $0.72 | $0.64 | $0.51 | $0.70 | $0.45 | $0.27 |